热毒宁注射液联合头孢他啶钠治疗支原体肺炎患者的安全性及可行性(1)
[摘要] 目的 分析熱毒宁注射液与头孢他啶钠联用对支原体肺炎成年患者的临床疗效和安全性。 方法 选取哈尔滨医科大学附属第一医院2016年4月～2017年7月收治的110例支原体肺炎成年患者作为研究对象，按照患者收治先后顺序标号进行盲法随机分为实验组(55例)与对照组(55例)，实验组采用热毒宁注射液联合头孢他啶钠治疗方法，对照组仅采用头孢他啶钠治疗方法。比较两组的肺炎症状好转时间差异、血清C-反应蛋白(CRP)数据变化以及组间治疗有效率。记录并比较两组不良反应发生情况。 结果 实验组治疗后的肺啰音及阴影减退速度、咳喘发热症状缓解时间和住院总时间短于对照组，差异有统计学意义(P < 0.05)；两组治疗后的CRP水平均低于治疗前，且实验组低于对照组，差异有统计学意义(P < 0.05)；实验组治疗后的总有效率为96.36%，明显高于对照组的83.64%，差异有统计学意义(P < 0.05)；所有患者在药物治疗期间均未出现严重不良反应症状，实验组的不良反应发生率低于治疗前，差异有统计学意义(P < 0.05)。 结论 与单一使用头孢他啶钠比较，热毒宁注射液联合头孢他啶钠治疗支原体肺炎成年患者的临床效果更好，能使患者各项临床症状与体征指标得到好转，并且安全性较好。
[关键词] 热毒宁注射液；头孢他啶钠；肺炎支原体；有效性
[中图分类号] R563 [文献标识码] A [文章编号] 1673-7210(2018)08(a)-0139-04
[Abstract] Objective To analyze the clinical safety and efficacy of Reduning Injection combined with Ceftazidime Sodium in treatment for Mycoplasma Pneumoniae pneumonia. Methods A total of 110 patients from April 2016 to July 2017 treated in the First Affiliated Hospital of Harbin Medical University with Mycoplasma Pneumoniae pneumonia were selected as research objects， and they were randomly divided into experimental group and control group via blind method， with 55 patients in each group. The experimental group was treated by Reduning Injection combined with Ceftazidime Sodium， while the control group was treated by Ceftazidime Sodium. Improvement time of symptoms， serum C-reactive protein (CRP)， effective rate and adverse reactions between the two groups were compared. Results The disappearing time of pulmonary moist rales， chest X-ray shadows， fever， cough and wheezing in experimental group were significantly shorten than those in control group， the differences were statistically significant (P < 0.05). The hospitalization time in experimental group was significantly less than that in control group， the difference was statistically significant (P < 0.05). After treatment， the levels of CRP in the two groups were lower than those of the before treatment， and the experimental group was lower than that in control group， the difference was statistically significant (P < 0.05). The total effective rate in experimental group was 96.36%， which was significantly higher than that in control group (83.64%)， the difference was statistically significant (P < 0.05). No severe adverse reactions occurred in the two groups. The incidence rate of adverse reactions in experimental group was significantly lower than that in control group， the difference was statistically significant (P < 0.05). Conclusion The effect of Reduning Injection combined with Ceftazidime Sodium in treatment for Mycoplasma Pneumoniae pneumonia is better， that can alleviate the shortterm inflammatory reaction， improve the symptoms， inhibit aggravation of the disease， and reduce adverse reactions. The safety of Reduning Injection combined with Ceftazidime Sodium is good., 百拇医药(潘博 高靖宇)
[关键词] 热毒宁注射液；头孢他啶钠；肺炎支原体；有效性
[中图分类号] R563 [文献标识码] A [文章编号] 1673-7210(2018)08(a)-0139-04
[Abstract] Objective To analyze the clinical safety and efficacy of Reduning Injection combined with Ceftazidime Sodium in treatment for Mycoplasma Pneumoniae pneumonia. Methods A total of 110 patients from April 2016 to July 2017 treated in the First Affiliated Hospital of Harbin Medical University with Mycoplasma Pneumoniae pneumonia were selected as research objects， and they were randomly divided into experimental group and control group via blind method， with 55 patients in each group. The experimental group was treated by Reduning Injection combined with Ceftazidime Sodium， while the control group was treated by Ceftazidime Sodium. Improvement time of symptoms， serum C-reactive protein (CRP)， effective rate and adverse reactions between the two groups were compared. Results The disappearing time of pulmonary moist rales， chest X-ray shadows， fever， cough and wheezing in experimental group were significantly shorten than those in control group， the differences were statistically significant (P < 0.05). The hospitalization time in experimental group was significantly less than that in control group， the difference was statistically significant (P < 0.05). After treatment， the levels of CRP in the two groups were lower than those of the before treatment， and the experimental group was lower than that in control group， the difference was statistically significant (P < 0.05). The total effective rate in experimental group was 96.36%， which was significantly higher than that in control group (83.64%)， the difference was statistically significant (P < 0.05). No severe adverse reactions occurred in the two groups. The incidence rate of adverse reactions in experimental group was significantly lower than that in control group， the difference was statistically significant (P < 0.05). Conclusion The effect of Reduning Injection combined with Ceftazidime Sodium in treatment for Mycoplasma Pneumoniae pneumonia is better， that can alleviate the shortterm inflammatory reaction， improve the symptoms， inhibit aggravation of the disease， and reduce adverse reactions. The safety of Reduning Injection combined with Ceftazidime Sodium is good., 百拇医药(潘博 高靖宇)